Trial Highlights

Elamipretide is an investigational drug with the potential to modify disease through its apparent ability to restore normal energy production in damaged mitochondria, while decreasing oxidative stress.8 This clinical candidate is being developed for both rare and common diseases, representing a novel therapeutic approach with the potential to treat a wide variety of unmet patient needs.

Our systemic clinical programs highlight several therapeutic areas, including cardiorenal indications and rare mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, we are leading mitochondrial medicine.

Systemic Formulation of Elamipretide in Clinical Studies

Rare Diseases

  • MMPOWER-3 Primary Mitochondrial Myopathy

    A phase 3 randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy and safety of daily subcutaneous injections of elamipretide in subjects with primary mitochondrial myopathy (PMM) followed by an open-label treatment extension.
    Learn more about this study

  • TAZPOWER Barth Syndrome

    A randomized, double-blind, placebo-controlled phase 2/3 crossover study to evaluate the safety, tolerability and efficacy of 12 weeks’ treatment with daily subcutaneous injections of elamipretide in individuals with genetically confirmed Barth syndrome followed by an open-label treatment extension.
    Learn more about this study


Observational Study


Cardiorenal Diseases


Completed Clinical Trials

Elamipretide in Clinical Trials

For more information, visit www.clinicaltrials.gov and search ‘Stealth BioTherapeutics’.